SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.63-$0.04 (-5.88%)
 
Market cap
$217M
Insider Score
Health Score
Analyst consensus
Listed since
Oct 11, 2018
Market Cap$217.48M-53.5%
Revenue (ttm)$4.64M
Net Income-$174.46M+17.7%
EPS-$0.63+35.7%
Shares Out346.47M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,579,436
Open$0.65
Previous Close$0.67
Day's Range$0.62 - $0.67
52-Week Range$0.62 - $4.46
Beta0.48
AnalystsBuy
Price Target$6.43(+924.37%)
Earnings DateMar 11, 2027

About ALLO

Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.

Address
210 East Grand Avenue, South San Francisco, CA, 94080, US
Market Cap
217 million
Employees
151
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$714.98K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From ALLO’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.88%
5 Days
-25.12%
1 Month
-49.78%
6 Months
-68.61%
1 Year
-53.50%

$ALLO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ALLO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ALLO's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ALLO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ALLO Revenue by Segment

$45.14MTotal
Payroll$15.40M34.12%
Cema-cel$13.95M30.90%
Facilities & IT-related spend$6.99M15.48%
Supporting external spend$5.73M12.69%
All other development costs$3.07M6.80%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ALLO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ALLO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ALLO

VTIVanguard Morningstar Total Stock Market ETF$8.06M
XBIState Street SPDR S&P Biotech ETF$6.33M
IWMiShares Russell 2000 ETF$4.47M
VXFVanguard Extended Market ETF$3.70M
VTWOVanguard Russell 2000 ETF$1.84M
IWNiShares Russell 2000 Value ETF$1.55M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ALLO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
0
Sells
16
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-45.0 since Aug 26
0255075100Aug 26 — Insider Score 45.0Aug 27 — Insider Score 45.0Aug 28 — Insider Score 45.0Aug 29 — Insider Score 45.0Aug 30 — Insider Score 45.0Aug 31 — Insider Score 45.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 34.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 26Sep 14Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

CNCRLoncar Cancer Immunotherapy ETF3.29%
MOONDirexion Moonshot Innovators ETF2.37%
NIFEDirexion Fallen Knives ETF0.99%
WDNAWisdomTree BioRevolution Fund0.37%
BBCVirtus Biotech Clinical Trials ETF0.35%
SBIOALPS Medical Breakthroughs ETF0.19%
PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF0.13%
BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF0.09%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.09%
XBIState Street SPDR S&P Biotech ETF0.08%
VFMOVanguard U.S. Momentum Factor ETF0.07%
MEDXHorizon Kinetics Medical ETF0.07%

Weight is the stock’s share of each fund’s holdings.